Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA 2005 Budget Request Omits Boost For OTCs, Asks For CDER FTE Cutbacks

This article was originally published in The Tan Sheet

Executive Summary

FDA's fiscal 2005 budget request provides no new increase for over-the-counter drug activities

You may also be interested in...



2006 Budget Request Aims To Build Drug Safety; OTC Spending Likely Flat

The Bush Administration's fiscal 2006 budget request represents a shift in resources toward drug safety activities within the Center for Drug Evaluation & Research

2006 Budget Request Aims To Build Drug Safety; OTC Spending Likely Flat

The Bush Administration's fiscal 2006 budget request represents a shift in resources toward drug safety activities within the Center for Drug Evaluation & Research

2006 Budget Request Aims To Build Drug Safety; OTC Spending Likely Flat

The Bush Administration's fiscal 2006 budget request represents a shift in resources toward drug safety activities within the Center for Drug Evaluation & Research

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel